Literature DB >> 23764663

[A methodology to implement preventive actions against harmful drug use in the context of primary health care in Latin America].

Pedro Henrique Antunes da Costa1, Daniela Cristina Belchior Mota, Erica Cruvinel, Fernando Santana de Paiva, Telmo Mota Ronzani.   

Abstract

OBJECTIVE: To develop a methodology to implement practices of prevention against the use of alcohol and other drugs in the context of primary health care (PHC) that will contribute to the debate about policies and actions in Latin American countries.
METHODS: This intervention research project was carried out in a small/medium-sized Brazilian city. The development process was assessed through participant observation with the aim of adapting the methodology to local needs and identifying existing weaknesses and strengths with impact on implementation.
RESULTS: A model was developed with six stages: initial contact and planning, diagnosis and mapping, sensitization, training, follow-up, and communication of results to participants. The following weaknesses were identified: limitation of resources (human, financial, infrastructural), limitations in the coverage and comprehensiveness of the assistance network, poor participation from physicians, training based on medicalized care, insufficient participation of health care management, insufficient involvement and participation of civil society, and few opportunities for participation of the population in the planning and execution of public policies. Strengths included the participation of community health agents and nurses in applying, organizing, and planning initiatives, in addition to the organization of educative and preventive actions in schools and communities by health care teams, suggesting that it is possible to implement screening, brief intervention, and referral to treatment (SBIRT) initiatives in the context of PHC in Latin America.
CONCLUSIONS: The methodology developed in this study can be useful for Latin American countries if local needs are taken into consideration. It should be noted, however, that results will only be observed in the mid- to long term, rather than strictly in the short term.

Entities:  

Mesh:

Year:  2013        PMID: 23764663     DOI: 10.1590/s1020-49892013000500003

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


  3 in total

1.  Scaling-up primary health care-based prevention and management of heavy drinking at the municipal level in middle-income countries in Latin America: Background and protocol for a three-country quasi-experimental study.

Authors:  Peter Anderson; Amy O'Donnell; Eileen Kaner; Antoni Gual; Bernd Schulte; Augusto Pérez Gómez; Hein de Vries; Guillermina Natera Rey; Jürgen Rehm
Journal:  F1000Res       Date:  2017-03-23

2.  Implementing primary healthcare-based measurement, advice and treatment for heavy drinking and comorbid depression at the municipal level in three Latin American countries: final protocol for a quasiexperimental study (SCALA study).

Authors:  Eva Jané-Llopis; Peter Anderson; Marina Piazza; Amy O'Donnell; Antoni Gual; Bernd Schulte; Augusto Pérez Gómez; Hein de Vries; Guillermina Natera Rey; Daša Kokole; Ines V Bustamante; Fleur Braddick; Juliana Mejía Trujillo; Adriana Solovei; Alexandra Pérez De León; Eileen Fs Kaner; Silvia Matrai; Jakob Manthey; Liesbeth Mercken; Hugo López-Pelayo; Gillian Rowlands; Christiane Schmidt; Jürgen Rehm
Journal:  BMJ Open       Date:  2020-07-28       Impact factor: 2.692

3.  Impact of Training and Municipal Support on Primary Health Care-Based Measurement of Alcohol Consumption in Three Latin American Countries: 5-Month Outcome Results of the Quasi-experimental Randomized SCALA Trial.

Authors:  Peter Anderson; Jakob Manthey; Eva Jané Llopis; Guillermina Natera Rey; Ines V Bustamante; Marina Piazza; Perla Sonia Medina Aguilar; Juliana Mejía-Trujillo; Augusto Pérez-Gómez; Gill Rowlands; Hugo Lopez-Pelayo; Liesbeth Mercken; Dasa Kokole; Amy O'Donnell; Adriana Solovei; Eileen Kaner; Bernd Schulte; Hein de Vries; Christiane Schmidt; Antoni Gual; Jürgen Rehm
Journal:  J Gen Intern Med       Date:  2021-01-19       Impact factor: 5.128

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.